Tools provided to professionals, policy-makers and researchers who wish to evaluate their interventions in the field of health, especially in drug-related harm reduction issues.
Detection of problem cannabis use : the Cannabis Abuse Screening Test (CAST), September 2013, 10 pages.
As the most widely-used illegal substance in France, more than one third of French 17-year-olds had used cannabis in the last year in 2011, and 7 out of 100 of them used it regularly (at least 10 times in the last month). To better understand the health and social problems likely to accompany this cannabis use, the French Monitoring Centre for Drugs and Drug Addiction (OFDT) developed a scale for identifying problem cannabis use. This scale is called the Cannabis Abuse Screening Test, or CAST. The OFDT's May 2013 publication of Drugs, addictions and key data provided an opportunity to conduct an initial survey of the proportion of 17-year-olds with a high risk for problem drug use in France. This memorandum refers to the implementation of this scale and the calculation of our estimate.
Guidelines for the implementation of good evaluation practices: Evaluating harm-reduction interventions, August 2009, 23 pages.
These guidelines are the result of the work carried out within the framework of the Addictions Committee set up by the Ministry of Health in November 2006. The purpose of this committee is to assess drug addict users' needs and improve public health and social responses (Decree of 26th October 2006). It was produced under the overall coordination of the French Monitoring Centre for Drugs and Drug Addictions (OFDT) by the working group appointed by the Addictions Committee to submit recommendations for evaluation in the harm reduction field. This working group brought together representatives from the health authorities, health professionals and harm reduction outreach practitioners. It carried out its work by applying the recommendations for good evaluation practices defined by the National Office for the Quality and Evaluation of Care and Social Services and Centres (ANESM). It proposes adapting the ANESM's official recommendations in order that these may be used in the field of harm reduction for drug users. The content of this document also draws upon the evaluation-specific recommendations of various international bodies (EMCDDA, WHO, UNODC).
These guidelines are accompanied by a fold-out diagram presenting the logic model or theory of action for the harm reduction interventions. It has been designed to supply key stakeholders with a useful tool to help them formulate potential evaluation questions of interest and define their assessment framework.
Keep in mind: For the best legibility of the tool, printing must be done in A1 format (poster format).
Protocols, guidelines and other methodological approaches to data collection in the field of drug use.
Data collection protocol for specialist harm reduction agencies
The booklet scribes the development and the field testing of a data collection protocol for harm reduction agencies and presents the final tool, including a manual.
Seven european countries were involved in this project whose purpose was to develop a common model of an Early Information Function for Emerging Drug Phenomena.
Drugs in Europe
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
What do the latest data tell us about drug production and trafficking trends?
These and other questions are explored in the 2020 European Drug Report, our annual overview of the drug situation in Europe.
Statistical Bulletin 2020
The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.